A detailed history of Tower Research Capital LLC (Trc) transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,802 shares of INZY stock, worth $4,901. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,802
Previous 6,519 72.36%
Holding current value
$4,901
Previous $29,000 68.97%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.31 - $6.0 $20,330 - $28,302
-4,717 Reduced 72.36%
1,802 $9,000
Q2 2024

Aug 13, 2024

BUY
$4.33 - $7.31 $26,503 - $44,744
6,121 Added 1537.94%
6,519 $29,000
Q1 2024

May 15, 2024

SELL
$4.14 - $7.66 $14,465 - $26,764
-3,494 Reduced 89.77%
398 $3,000
Q4 2023

Feb 13, 2024

SELL
$2.71 - $4.5 $12,032 - $19,980
-4,440 Reduced 53.29%
3,892 $16,000
Q3 2023

Nov 14, 2023

BUY
$4.09 - $7.0 $19,537 - $33,439
4,777 Added 134.37%
8,332 $34,000
Q2 2023

Aug 14, 2023

SELL
$4.93 - $6.74 $51,952 - $71,026
-10,538 Reduced 74.77%
3,555 $19,000
Q1 2023

May 09, 2023

BUY
$1.3 - $5.73 $13,643 - $60,136
10,495 Added 291.69%
14,093 $81,000
Q4 2022

Feb 10, 2023

BUY
$1.05 - $2.82 $3,777 - $10,146
3,598 New
3,598 $4,000
Q2 2022

Aug 15, 2022

SELL
$3.2 - $5.96 $7,776 - $14,482
-2,430 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$3.87 - $7.55 $3,978 - $7,761
1,028 Added 73.32%
2,430 $10,000
Q4 2021

Feb 14, 2022

BUY
$5.58 - $11.5 $3,331 - $6,865
597 Added 74.16%
1,402 $10,000
Q3 2021

Nov 15, 2021

SELL
$11.12 - $19.4 $4,158 - $7,255
-374 Reduced 31.72%
805 $9,000
Q2 2021

Aug 16, 2021

BUY
$15.19 - $21.2 $303 - $424
20 Added 1.73%
1,179 $20,000
Q1 2021

May 17, 2021

SELL
$17.77 - $27.9 $4,282 - $6,723
-241 Reduced 17.21%
1,159 $23,000
Q4 2020

Feb 16, 2021

BUY
$19.95 - $27.55 $2,812 - $3,884
141 Added 11.2%
1,400 $29,000
Q3 2020

Nov 16, 2020

BUY
$17.54 - $30.2 $22,082 - $38,021
1,259 New
1,259 $33,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $109M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.